Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 2/20 | 0.38 |
| ▸ | AR | P10275 | 3/20 | 0.35 |
| ▸ | HRH2 | P25021 | 4/20 | 0.35 |
| ▸ | HRH1 | P35367 | 4/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 5/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7243876 | 0.92 | CCR3 (0.38) | CCR3ARHRH2HRH1HRH3 | |
| SCHEMBL7244769 | 0.90 | CCR3 (0.37) | CCR3ARHRH2HRH1HRH3 | |
| SCHEMBL7245194 | 0.85 | HRH3 (0.39) | CCR3HRH2HRH1HRH3MEN1 | |
| SCHEMBL7248406 | 0.84 | HRH2 (0.37) | HRH2HRH1HRH3PDK2MEN1 | |
| SCHEMBL7252505 | 0.84 | CYP2D6 (0.41) | CCR3ARHRH2HRH1HRH3 | |
| SCHEMBL7243339 | 0.84 | HRH2 (0.44) | HRH2HRH1HRH3MEN1 | |
| SCHEMBL7245391 | 0.83 | HRH2 (0.39) | CCR3HRH2HRH1HRH3MEN1 | |
| SCHEMBL7242815 | 0.83 | CCR3 (0.41) | CCR3ARHRH2HRH1HRH3 | |
| SCHEMBL6093467 | 0.83 | HRH2 (0.37) | CCR3ARHRH2HRH1HRH3 | |
| SCHEMBL7244486 | 0.82 | CCR3 (0.36) | CCR3ARHRH2HRH1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6559162-B2 | Electrophysiological activity | ASTRAZENECA AB (SE) | 2003-05-06 | — | — | US | disclosed |
| US-20020137766-A1 | Azabicyclooctane derivatives useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137766-A1 | Azabicyclooctane derivatives useful in the treatment of cardiac arrhythmias | KCNH1, KCNH2, KCNH3 | CCR3 2275/4885AR 2213/4885HRH2 321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.